Only 4 spots left

~4 spots leftby Dec 2025

Xenon MRI for Chronic Lung Disease

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byGrace E Parraga, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Western University, Canada

Disqualifiers: Pregnancy, Claustrophobia, MRI incompatible devices, others

No Placebo Group

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

Subjects aged 18-85 with lung disease will undergo hyperpolarized Xenon 129 (129-Xe) MRI and Pulmonary Function testing for the development of tools to evaluate the Apparent Diffusion Coefficient (ADC), ventilation defect percent (VDP) and pulmonary gas exchange measurements obtained by analysis of hyperpolarized 129-Xe MRI.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Hyperpolarized Xenon 129 for chronic lung disease?

Research shows that Hyperpolarized Xenon 129 MRI is effective in assessing lung functions like ventilation and gas transfer, which are crucial for managing chronic lung diseases such as COPD (chronic obstructive pulmonary disease). This imaging technique provides detailed insights into lung physiology, making it a promising tool for evaluating and managing lung conditions.¹ ² ³ ⁴ ⁵

How is Xenon MRI different from other treatments for chronic lung disease?

Xenon MRI is unique because it uses hyperpolarized xenon gas to provide detailed images of lung function, specifically assessing both ventilation and gas transfer, which is not possible with standard imaging techniques. This method offers a non-invasive way to evaluate lung physiology and can help in managing chronic lung diseases by identifying ventilation-perfusion mismatches and tracking treatment success.¹ ⁴ ⁵ ⁶ ⁷

Research Team

Grace E Parraga, PhD

Principal Investigator

Robarts Research Institute, The University of Western Ontario

Eligibility Criteria

This trial is for adults aged 18-85 with lung diseases like asthma, COPD, or pulmonary fibrosis. Participants must be able to understand the study and consent to it, have a certain level of lung function (FEV1 >25% predicted), and be in stable health. They can't join if they're pregnant, have MRI-incompatible devices in their body, severe claustrophobia, oxygen saturation too low, or conditions preventing them from performing required tests.

Inclusion Criteria

Subject is judged to be in otherwise stable health on the basis of medical history

Your lung capacity is greater than 25% of what is expected and is more than 0.5 liter.

I am between 18-85 years old with a diagnosed lung condition.

See 4 more

Exclusion Criteria

I am able to understand and consent to my own medical treatment.

I have a metal device or object in my body that cannot be removed.

Patient is pregnant or lactating

See 4 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

1 visit (in-person)

Baseline Assessment

Participants undergo informed consent, medical history, vital signs, full pulmonary function tests, proton MRI, and 129-Xe MRI

1-2 hours

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after baseline assessment

5 years

Multiple visits over 5 years

Treatment Details

Interventions

Hyperpolarized Xenon 129 (Gas)

Trial OverviewThe trial involves using a special type of MRI called hyperpolarized Xenon 129 MRI along with Pulmonary Function testing. These tools will help measure different aspects of lung function such as gas exchange and airway obstruction in people with chronic lung disease.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: MRI at baseline and over timeExperimental Treatment1 Intervention

Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Western University, Canada

Lead Sponsor

Trials

270

Recruited

62,500+

Dr. Robin Farias-Eisner

Western University, Canada

Chief Executive Officer since 2022

PhD in Molecular Biology from UCLA, MD from the Royal College of Surgeons in Dublin, MBA from Pepperdine University

James Tweedy

Western University, Canada

Chief Medical Officer since 2020

MBA from Trinity Western University

Findings from Research

The recent FDA approval of hyperpolarized 129Xe as an MR contrast agent highlights its growing importance in lung imaging, prompting the need for standardized techniques across research and clinical sites.

The 129Xe MRI Clinical Trials Consortium has established best practices for the entire workflow of 129Xe MRI, including safety monitoring and technical considerations, to ensure effective and safe imaging of lung ventilation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Acquiring Hyperpolarized 129Xe Magnetic Resonance Images of Lung Ventilation.Garrison, WJ., Mugler, JP., Mata, JF., et al.[2023]

The continuous flow-type hyperpolarizing (CF-HP) system allows for effective lung imaging using hyperpolarized (129)Xe MRI at very low concentrations of xenon, minimizing the anesthetic effects and reducing xenon consumption.

Using a 70% xenon gas mixture resulted in better signal-to-noise ratios for both gas and dissolved-phase images compared to a 3% mixture, although the apparent diffusion coefficient (ADC) was higher with the 3% mixture, indicating a complex relationship between concentration and imaging quality.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Hyperpolarized 129 Xe MRI of the mouse lung at a low xenon concentration using a continuous flow-type hyperpolarizing system.Wakayama, T., Kitamoto, M., Ueyama, T., et al.[2015]